Analysis of E6/E7 mRNA gene expression by means of NucliSENS EasyQ (NASBA) technique in patients suffering from cervical dysplasia with HPV positive

Objective: In this study, the authors aimed at examining E6/E7 mRNA gene expression by means of NucliSENS EasyQ (NASBA) in patients in which HPV infection was detected and diagnosed with cervical dysplasia. Materials and Methods: This study included 77 patients diagnosed with cervical dysplasia. The patients were grouped based on cervico-vaginal smear anomalies. Digene HC2 DNA Collection Device transport medium was used for taking and keeping cervical samples, QIA symphony SP device, and QIAsymphony DSP AXpH DNA kit were used for HPV DNA extraction from cervical samples kept in transport medium, HPV Q24 complete kit, RotorGene and PyroMark Q24 for detection of HPV-DNA and determination of HPV types and NucliSENS Easy Q Genetic Analyzer technique for determination of E6/E7 gene expression in HPV positive samples. SPSS (Statistical Package for Social Sciences) Version 22.0 was employed in statistical evaluation of the research date. Results: The most common HPV was considered as type 16 in this study. When pathology specimens of patients in whom dysplasia was detected in their cervical biopsies were examined in terms of HPV E6/E7 mRNA expression, a statistically significant difference was found between the normal and pathology groups (p < 0.05). Conclusion: Today, the presence of HPV infection in etiology of cervical smear pathologies and dysplasia is undisputedly accepted. The main determinant factor of HPV virulence is the frequency of E6 and E7 gene expressions existing in the DNA structure and responsible for virulence. NucliSENS EasyQ (NASBA) is a technique employed to analyze mRNA gene expression in an accurate, reliable, and rapid way. Parallel to the conclusions of studies in the literature, frequency of E6/E7 gene expression increases in proportion to the increasing dysplasia degree of cervical pathologies in the present study as well.

Cervical dysplasia; HPV, NucliSENS EasyQ (NASBA) technique; E6/E7.

[1] Parkin D.M., Bray F., Ferlay J., Pisani P.: “Global cancer statistics, 2002”. CA Cancer J. Clin., 2005, 55, 74.

[2] Schiffman M.H., Brinton L.A.: “The epidemiology of cervical carcinogenesis”. Cancer, 1995, 76, 1888.

[3] Solomon D., Davey D., Kurman R., Moriarty A., O'Connor D., Prey M., et al.: “The 2001 Bethesda System: Terminology for reporting results of cervical cytology”. JAMA, 2002, 287, 2114.

[4] Saslow D., Runowicz C.D., Solomon D., Moscicki A.B., Smith R.A., Eyre H.J., et al.: “American Cancer Society guidelines for the early detection of cervical neoplasia and cancer. American Cancer Society”. CA Cancer J. Clin., 2002, 52, 342.

[5] Clifford G.M., Gallus S., Herrero R., Muñoz N., Snijders P.J., Vaccarella S., et al.: “HPV Prevalence Surveys Study Group:Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis”. Lancet, 2005, 366, 991.

[6] Dursun P., Senger S.S., Arslan H., Kuscu E., Ayhan A.: “Human papillomavirus (HPV) prevalence and types among Turkish women at a gynecology outpatient unit”. BMC Infect Dis., 2009, 9, 191.

[7] Ronco G., Giorgi Rossi P., Giubilato P., Del Mistro A., Zappa M., Carozzi F.: “A first survey of HPV-based screening in routine cervical cancer screening in Italy”. Epidemiol. Prev., 2015, 39, 77.

[8] Yilmaz E., Celik O., Celik E., Turkcuoglu I., Simsek Y., Karaer A., et al.: “XPD and XRCC1 gene polymorphism in patients with normal and abnormal cervical cytology by pap smear”. Eur. Rev. Med. Pharmacol. Sci., 2012, 16, 1713.

[9] Song D., Li H., Li H., Dai J.: “Effect of human papillomavirus infection on the immune system and its role in the course of cervical cancer”. Oncol Lett., 2015, 10, 600.

[10] Hu D., Zhou J., Wang F., Shi H., Li Y,. Li B.: “HPV-16 E6/E7 promotes cell migration and invasion in cervical cancer via regulating cadherin switch in vitro and in vivo”. Arch. Gynecol. Obstet., 2015, 292, 1345.

[11] Duvlis S., Popovska-Jankovic K., Arsova Z.S., Memeti S., Popeska Z., Plaseska-Karanfilska D.: “HPV E6/E7 mRNA versus HPV DNA biomarker in cervical cancer screening of a group of Macedonian women”. J. Med. Virol., 2015, 87, 1578.

[12] Munkhdelger J., Choi Y., Lee D., Kim S., Kim G., Park S., et al.: “Comparison of the performance of the NucliSENS EasyQ HPV E6/E7 mRNA assay and HPV DNA chip for testing squamous cell lesions of the uterine cervix”. Diagn. Microbiol. Infect. Dis., 2014, 79, 422.

[13] Tezcan S., Ozgur D., Ulger M., Aslan G., Gurses I., Serin M.S., et al.: “Human papillomavirus genotype distribution and E6/E7 oncogene expression in Turkish women with cervical cytological findings”. Asian Pac. J. Cancer Prev., 2014, 15, 3997.

[14] Padalko E., Van Renterghem L., Bamelis M., De Mey A., Sturtewagen Y., Vastenavond H., et al.: “Prospective evaluation of E6/E7 mRNA detection by the NucliSENS Easy Q HPV assay in a stepwise protocol”. J. Med. Virol., 2013, 85, 1242.

[15] Salimovi-Beai I., Tomić-Čiča A., Smailji A., Hukić M.: “Comparison of the detection of HPV-16, 18, 31, 33, and 45 by type-specific DNA- and E6/E7 mRNA-based assays of HPV DNA positive women with abnormal Pap smears”. J. Virol. Methods, 2013, 194, 222.

[16] Halfon P., Benmoura D., Agostini A., Khiri H., Martineau A., Penaranda G., Blanc B.: “Relevance of HPV mRNA detection in a population of ASCUS plus women using the NucliSENS EasyQ HPVassay”. J. Clin. Virol., 2010, 47, 177.